产品名称
SW48 Cells BAX/BAK (-/-,-/-),
biological source
human female colon (Source Disease: Colorectal adenocarcinoma)
OMIM accession no.
storage temp.
−196°C
Quality Level
General description
This product corresponds to ATCC Cat. No. CCL-231
Analysis Note
Tested for Mycoplasma, sterility, post-freeze viability, short terminal repeat (STR) analysis for cell line identification, PCR assay for cell line species confirmation.
Application
Media Renewal changes one to two times per week
Rapidly thaw vial by gentle agitation in 37°C water bath (~2 minutes), keeping vial cap out of the water. Decontaminate with 70% ethanol, add 9 mL culture media and centrifuge 125 x g (5-7 minutes). Resuspend in complete culture media and incubate at 37°C in a 5% CO2 atmosphere.
Subculture Ratio: approx. 1:2 to 1:6
The base medium for this cell line is DMEM, Cat. No. D5671. To make the complete growth medium, add the following components to the base medium: fetal bovine serum, Cat. No. F4135, to a final concentration (v/v) of 10%, Sodium pyruvate, Cat. No. S8636, at a final concentration of 1 mM, and L-glutamine, Cat. No. G7513, at a final concentration of 2mM.
The cell freezing medium is DMSO 1X (Cat. No. C6164)
Disclaimer
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
Features and Benefits
These SW48 cells are adherent, with a doubling time of approx. 35 hours.
Zinc finger nuclease (ZFN) double knock out on chromosome 19q13.3-13.4 / 6p21.3
存储类别
12 - Non Combustible Liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
高风险级别生物产品--人源产品
此项目有
Srividya B Balachander et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 26(24), 6535-6549 (2020-09-30)
Targeting Bcl-2 family members upregulated in multiple cancers has emerged as an important area of cancer therapeutics. While venetoclax, a Bcl-2-selective inhibitor, has had success in the clinic, another family member, Bcl-xL, has also emerged as an important target and
相关内容
Instructions
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持